SAN FRANCISCO – Eagerly awaited results of the CO.20 trial in metastatic chemorefractory KRAS wild-type colorectal cancer are disappointing, showing no significant gain in the primary endpoint of overall survival from the addition of brivanib to cetuximab. Patients in the phase-III trial who received brivanib – an investigational oral inhibitor of signaling in the vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) pathways – lived a median of about nine months, compared...